

Rossarin Suwanarusk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5893976/publications.pdf>

Version: 2024-02-01

51
papers

4,188
citations

172457

29
h-index

189892

50
g-index

51
all docs

51
docs citations

51
times ranked

5144
citing authors

#	ARTICLE	IF	CITATIONS
1	Spiroindolones, a Potent Compound Class for the Treatment of Malaria. <i>Science</i> , 2010, 329, 1175-1180.	12.6	1,031
2	Targeting Plasmodium PI(4)K to eliminate malaria. <i>Nature</i> , 2013, 504, 248-253.	27.8	377
3	On the Cytoadhesion of <i>Plasmodium vivax</i> Infected Erythrocytes. <i>Journal of Infectious Diseases</i> , 2010, 202, 638-647.	4.0	259
4	Chloroquine Resistant <i>Plasmodium vivax</i> : In Vitro Characterisation and Association with Molecular Polymorphisms. <i>PLoS ONE</i> , 2007, 2, e1089.	2.5	187
5	A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. <i>Scientific Reports</i> , 2011, 1, 118.	3.3	175
6	The Deformability of Red Blood Cells Parasitized by <i>Plasmodium falciparum</i> and <i>P. vivax</i> . <i>Journal of Infectious Diseases</i> , 2004, 189, 190-194.	4.0	162
7	<i>Plasmodium vivax</i> : restricted tropism and rapid remodeling of CD71-positive reticulocytes. <i>Blood</i> , 2015, 125, 1314-1324.	1.4	157
8	KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5060-5067.	3.2	122
9	A reliable ex vivo invasion assay of human reticulocytes by <i>Plasmodium vivax</i> . <i>Blood</i> , 2011, 118, e74-e81.	1.4	120
10	Determinants of In Vitro Drug Susceptibility Testing of <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1040-1045.	3.2	119
11	Cerebral malaria. <i>Virulence</i> , 2012, 3, 193-201.	4.4	118
12	Amplification of <i>pvm-dr1</i> Associated with Multidrug Resistant <i>Plasmodium vivax</i> . <i>Journal of Infectious Diseases</i> , 2008, 198, 1558-1564.	4.0	117
13	Significant Biochemical, Biophysical and Metabolic Diversity in Circulating Human Cord Blood Reticulocytes. <i>PLoS ONE</i> , 2013, 8, e76062.	2.5	114
14	Effective and cheap removal of leukocytes and platelets from <i>Plasmodium vivax</i> infected blood. <i>Malaria Journal</i> , 2009, 8, 115.	2.3	86
15	A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e114.	5.1	79
16	<i>Plasmodium vivax</i> Adherence to Placental Glycosaminoglycans. <i>PLoS ONE</i> , 2012, 7, e34509.	2.5	70
17	Comparison of three molecular methods for the detection and speciation of <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2007, 6, 124.	2.3	64
18	<i>Plasmodium vivax</i> trophozoites insensitive to chloroquine. <i>Malaria Journal</i> , 2008, 7, 94.	2.3	55

#	ARTICLE	IF	CITATIONS
19	Plasmodium vivax: Isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. <i>Experimental Parasitology</i> , 2006, 114, 34-39.	1.2	47
20	Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used for invasion and short term culture. <i>International Journal for Parasitology</i> , 2012, 42, 155-160.	3.1	44
21	Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes. <i>Blood</i> , 2014, 123, e100-e109.	1.4	44
22	Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax. <i>Frontiers in Immunology</i> , 2015, 6, 348.	4.8	44
23	Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 950-959.	3.2	43
24	Human ex vivo studies on asexual Plasmodium vivax: The best way forward. <i>International Journal for Parasitology</i> , 2012, 42, 1063-1070.	3.1	40
25	Quantitative mass spectrometry of human reticulocytes reveal proteome-wide modifications during maturation. <i>British Journal of Haematology</i> , 2018, 180, 118-133.	2.5	40
26	Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. <i>Nature Communications</i> , 2019, 10, 3635.	12.8	39
27	A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609. <i>Journal of Infectious Diseases</i> , 2016, 213, 100-104.	4.0	35
28	Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of <i>Plasmodium vivax</i> than against Those of <i>P. falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2435-2441.	3.2	34
29	Considerations on the use of nucleic acid-based amplification for malaria parasite detection. <i>Malaria Journal</i> , 2011, 10, 323.	2.3	34
30	Genomic Analysis Reveals a Common Breakpoint in Amplifications of the <i>Plasmodium vivax</i> Multidrug Resistance 1 Locus in Thailand. <i>Journal of Infectious Diseases</i> , 2016, 214, 1235-1242.	4.0	29
31	Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi. <i>Blood</i> , 2017, 130, 1357-1363.	1.4	27
32	Plasmodium vivax lineages: geographical distribution, tandem repeat polymorphism, and phylogenetic relationship. <i>Malaria Journal</i> , 2011, 10, 374.	2.3	26
33	Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells. <i>Nature Microbiology</i> , 2021, 6, 991-999.	13.3	26
34	Plasmodium vivax genetic diversity: microsatellite length matters. <i>Trends in Parasitology</i> , 2006, 22, 399-401.	3.3	25
35	Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 124-129.	3.0	23
36	Rheopathologic Consequence of Plasmodium vivax Rosette Formation. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004912.	3.0	20

#	ARTICLE	IF	CITATIONS
37	Field-Based Flow Cytometry for <i>Ex Vivo</i> Characterization of Plasmodium vivax and P. falciparum Antimalarial Sensitivity. Antimicrobial Agents and Chemotherapy, 2013, 57, 5170-5174.	3.2	18
38	<i>Plasmodium vivax</i> Susceptibility to Ferroquine. Antimicrobial Agents and Chemotherapy, 2010, 54, 2228-2230.	3.2	17
39	<i>In vitro</i> Antimalarial Evaluations and Cytotoxicity Investigations of <i>Carica papaya</i> Leaves and Carpaine. Natural Product Communications, 2019, 14, 1934578X1901400.	0.5	16
40	Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax. Journal of Infectious Diseases, 2011, 203, 207-210.	4.0	14
41	In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. Molecules, 2017, 22, 2102.	3.8	12
42	Genetic Diversity in New Members of the Reticulocyte Binding Protein Family in Thai Plasmodium vivax Isolates. PLoS ONE, 2012, 7, e32105.	2.5	12
43	Giemsa-Stained Wet Mount Based Method for Reticulocyte Quantification: A Viable Alternative in Resource Limited or Malaria Endemic Settings. PLoS ONE, 2013, 8, e60303.	2.5	11
44	The Presence of Leukocytes in <i>Ex Vivo</i> Assays Significantly Increases the 50-Percent Inhibitory Concentrations of Artesunate and Chloroquine against <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 1300-1304.	3.2	10
45	An amidation/cyclization approach to the synthesis of N-hydroxyquinolinones and their biological evaluation as potential anti-plasmodial, anti-bacterial, and iron(II)-chelating agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 607-610.	2.2	10
46	Asian G6PD-Mahidol Reticulocytes Sustain Normal Plasmodium Vivax Development. Journal of Infectious Diseases, 2017, 216, 263-266.	4.0	8
47	Improving in vitro continuous cultivation of Plasmodium cynomolgi, a model for P. vivax. Parasitology International, 2022, 89, 102589.	1.3	7
48	In silico epitope mapping and experimental evaluation of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) as a malaria vaccine candidate. Malaria Journal, 2018, 17, 20.	2.3	6
49	Medicinal Plants and Malaria. , 0, , .		6
50	Characterization of the Commercially-Available Fluorescent Chloroquine-BODIPY Conjugate, LynxTag-CQGREEN, as a Marker for Chloroquine Resistance and Uptake in a 96-Well Plate Assay. PLoS ONE, 2014, 9, e110800.	2.5	5
51	Longitudinal ex vivo and molecular trends of chloroquine and piperazine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 46-56.	3.4	4